Resources Blog Chinese Antibody Society (CAS) Annual Conference 2024 – Boston: Event Recap

Chinese Antibody Society (CAS) Annual Conference 2024 – Boston: Event Recap

Biointron 2024-05-12 Read time: 3 mins


The Chinese Antibody Society (CAS) Annual Conference 2024 was held in Boston, MA on May 11. The meeting was titled “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories” and featured the latest advancements in therapeutic antibodies, in addition to innovative approaches in their discovery, development, and manufacturing. Several prominent speakers in the biopharmaceutical field gave talks throughout the day.

Biointron Summary Report: 

1. Cancer Immunotherapy 

  • The keynote speaker of the day was Dr. Gordon Freeman from the Dana-Farber Cancer Institute, who gave insights into different types of studies on cancer therapies, the PD-L1 pathway, and isolation of functional monoclonal antibodies from experimental vaccines. 

  • Antibody-guided T-cell therapy as an alternative to CAR-T or TCR-T strategies. 

  • Targeting the CD24/Siglec-10 axis is a potential cancer therapy strategy based on the findings of current preclinical studies and clinical trial outcomes. 

2. Alzheimer’s Disease 

  • Developing antibodies targeting LILRB2/TREM2 to affect regulation of TREM2 functions, as both both LILRB2 and TREM2 are expressed in human brain microglia, which plays crucial roles in Alzheimer’s disease development. 

3. Bioinformatics 

  • Understanding the grammar and semantics of protein language models is important to use them as tools for predicting and designing protein structure and function. They learn from diverse sequences across the evolutionary tree. 

  • Quantifiication of the success of antibody therapeutics over history. 

4. Antibody Engineering 

  • Payload-linker and conjugation technologies for novel and superior ADCs. 

  • Engineering complex antigens and major histocompatibility complexes and multi-pass transmembrane proteins. 

  • Production of camel and shark VHH antibodies neutralizing SARS-CoV-2 and Lassa virus. 


Thank you to all who visited our booth at CAS! We had a fantastic time connecting with you and sharing how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at or visit our website at

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.